vs
亚什兰（ASH）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是Prestige Consumer Healthcare Inc.的1.4倍（$386.0M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs -3.1%，领先19.6%），Prestige Consumer Healthcare Inc.同比增速更快（-2.4% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $75.3M），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
ASH vs PBH — 直观对比
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $283.4M |
| 净利润 | $-12.0M | $46.7M |
| 毛利率 | 27.2% | 55.5% |
| 营业利润率 | -1.6% | 29.1% |
| 净利率 | -3.1% | 16.5% |
| 营收同比 | -4.7% | -2.4% |
| 净利润同比 | 92.7% | -23.5% |
| 每股收益（稀释后） | $-0.26 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $386.0M | $283.4M | ||
| Q3 25 | $477.0M | $274.1M | ||
| Q2 25 | $463.0M | $249.5M | ||
| Q1 25 | $479.0M | $296.5M | ||
| Q4 24 | $405.0M | $290.3M | ||
| Q3 24 | $521.0M | $283.8M | ||
| Q2 24 | $544.0M | $267.1M | ||
| Q1 24 | $575.0M | $277.0M |
| Q4 25 | $-12.0M | $46.7M | ||
| Q3 25 | $31.0M | $42.2M | ||
| Q2 25 | $-742.0M | $47.5M | ||
| Q1 25 | $31.0M | $50.1M | ||
| Q4 24 | $-165.0M | $61.0M | ||
| Q3 24 | $17.0M | $54.4M | ||
| Q2 24 | $6.0M | $49.1M | ||
| Q1 24 | $120.0M | $49.5M |
| Q4 25 | 27.2% | 55.5% | ||
| Q3 25 | 33.3% | 55.3% | ||
| Q2 25 | 28.5% | 56.2% | ||
| Q1 25 | 30.7% | 57.3% | ||
| Q4 24 | 27.4% | 55.5% | ||
| Q3 24 | 33.2% | 55.5% | ||
| Q2 24 | 34.2% | 54.7% | ||
| Q1 24 | 28.0% | 54.8% |
| Q4 25 | -1.6% | 29.1% | ||
| Q3 25 | 12.8% | 29.1% | ||
| Q2 25 | -152.9% | 28.8% | ||
| Q1 25 | 10.6% | 29.8% | ||
| Q4 24 | -44.2% | 31.7% | ||
| Q3 24 | 6.1% | 29.7% | ||
| Q2 24 | -11.2% | 27.0% | ||
| Q1 24 | 3.7% | 29.7% |
| Q4 25 | -3.1% | 16.5% | ||
| Q3 25 | 6.5% | 15.4% | ||
| Q2 25 | -160.3% | 19.0% | ||
| Q1 25 | 6.5% | 16.9% | ||
| Q4 24 | -40.7% | 21.0% | ||
| Q3 24 | 3.3% | 19.2% | ||
| Q2 24 | 1.1% | 18.4% | ||
| Q1 24 | 20.9% | 17.9% |
| Q4 25 | $-0.26 | $0.97 | ||
| Q3 25 | $0.83 | $0.86 | ||
| Q2 25 | $-16.21 | $0.95 | ||
| Q1 25 | $0.65 | $1.00 | ||
| Q4 24 | $-3.50 | $1.22 | ||
| Q3 24 | $0.34 | $1.09 | ||
| Q2 24 | $0.12 | $0.98 | ||
| Q1 24 | $2.39 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $62.4M |
| 总债务越低越好 | $1.4B | $1.0B |
| 股东权益账面价值 | $1.9B | $1.8B |
| 总资产 | $4.5B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.74× | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $304.0M | $62.4M | ||
| Q3 25 | $215.0M | $119.1M | ||
| Q2 25 | $207.0M | $139.5M | ||
| Q1 25 | $168.0M | $97.9M | ||
| Q4 24 | $219.0M | $50.9M | ||
| Q3 24 | $300.0M | $51.5M | ||
| Q2 24 | $399.0M | $34.3M | ||
| Q1 24 | $439.0M | $46.5M |
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.4B | $993.1M | ||
| Q2 25 | $1.4B | $992.7M | ||
| Q1 25 | $1.3B | $992.4M | ||
| Q4 24 | $1.3B | $992.0M | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.3B | $1.1B | ||
| Q1 24 | $1.3B | $1.1B |
| Q4 25 | $1.9B | $1.8B | ||
| Q3 25 | $1.9B | $1.8B | ||
| Q2 25 | $1.9B | $1.9B | ||
| Q1 25 | $2.6B | $1.8B | ||
| Q4 24 | $2.6B | $1.8B | ||
| Q3 24 | $2.9B | $1.7B | ||
| Q2 24 | $3.0B | $1.7B | ||
| Q1 24 | $3.1B | $1.7B |
| Q4 25 | $4.5B | $3.5B | ||
| Q3 25 | $4.6B | $3.4B | ||
| Q2 25 | $4.6B | $3.4B | ||
| Q1 25 | $5.2B | $3.4B | ||
| Q4 24 | $5.2B | $3.3B | ||
| Q3 24 | $5.6B | $3.3B | ||
| Q2 24 | $5.7B | $3.3B | ||
| Q1 24 | $5.9B | $3.3B |
| Q4 25 | 0.74× | 0.56× | ||
| Q3 25 | 0.73× | 0.54× | ||
| Q2 25 | 0.73× | 0.54× | ||
| Q1 25 | 0.52× | 0.54× | ||
| Q4 24 | 0.51× | 0.55× | ||
| Q3 24 | 0.47× | 0.61× | ||
| Q2 24 | 0.45× | 0.65× | ||
| Q1 24 | 0.42× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $75.3M |
| 自由现金流率自由现金流/营收 | 28.8% | 26.6% |
| 资本支出强度资本支出/营收 | 3.6% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 1.68× |
| 过去12个月自由现金流最近4个季度 | $200.0M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $125.0M | $78.3M | ||
| Q3 25 | $40.0M | $57.5M | ||
| Q2 25 | $115.0M | $79.0M | ||
| Q1 25 | $9.0M | $61.8M | ||
| Q4 24 | $-30.0M | $65.1M | ||
| Q3 24 | $80.0M | $69.8M | ||
| Q2 24 | $127.0M | $54.8M | ||
| Q1 24 | $54.0M | $66.9M |
| Q4 25 | $111.0M | $75.3M | ||
| Q3 25 | $6.0M | $55.4M | ||
| Q2 25 | $95.0M | $78.2M | ||
| Q1 25 | $-12.0M | $58.4M | ||
| Q4 24 | $-53.0M | $63.5M | ||
| Q3 24 | $42.0M | $67.8M | ||
| Q2 24 | $98.0M | $53.6M | ||
| Q1 24 | $20.0M | $63.8M |
| Q4 25 | 28.8% | 26.6% | ||
| Q3 25 | 1.3% | 20.2% | ||
| Q2 25 | 20.5% | 31.3% | ||
| Q1 25 | -2.5% | 19.7% | ||
| Q4 24 | -13.1% | 21.9% | ||
| Q3 24 | 8.1% | 23.9% | ||
| Q2 24 | 18.0% | 20.1% | ||
| Q1 24 | 3.5% | 23.0% |
| Q4 25 | 3.6% | 1.1% | ||
| Q3 25 | 7.1% | 0.8% | ||
| Q2 25 | 4.3% | 0.3% | ||
| Q1 25 | 4.4% | 1.2% | ||
| Q4 24 | 5.7% | 0.5% | ||
| Q3 24 | 7.3% | 0.7% | ||
| Q2 24 | 5.3% | 0.4% | ||
| Q1 24 | 5.9% | 1.1% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | 1.29× | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | 0.29× | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | 4.71× | 1.28× | ||
| Q2 24 | 21.17× | 1.12× | ||
| Q1 24 | 0.45× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
